DR. PETER MICHAEL LEVINE, M.D.
Psychiatric at Montrose Rd, Rockville, MD

7333895, Feb 19, 2008

Jul 28, 2003

10/628135

Ben A. Hitt - Gaithersburg MD, US
Peter J. Levine - Potomac MD, US
Timothy A. Coleman - Derwood MD, US

Correlogic Systems, Inc. - Rockville MD

G06F 19/00

702 19

The invention relates to a method of quality assurance/quality control for high-throughput bioassay processes. The method permits monitoring of an entire system for obtaining spectral data from biological samples. Generally, the method includes generating a bioassay process model, comparing a test sample against the bioassay process model. The bioassay process model may be based on the position of a centroid in n-dimensional space. The comparing may include comparing the location of a centroid associated with the test model against the centroid associated with the control model to determine the distance between the two centroids. By generating a trend plot of the distance between the centroid associated with the test sample and the centroid associated with the control model, overall system performance may be monitored over time.

7761239, Jul 20, 2010

Dec 10, 2004

11/008784

Ben A. Hitt - Wheeling WV, US
Peter J. Levine - Potomac MD, US

Correlogic Systems, Inc. - Germantown MD

G06F 19/00, G06F 7/00, G01N 31/00, G01N 24/00

702 19, 702 22, 702 27, 702 32, 436173

A model of a particular biological state can be developed. The model may be used to determine if an unknown biological sample exhibits a particular biological state. This can be done by receiving either a biological sample or data associated with the biological sample. After the data is received, the data may be input into the model. In one embodiment, the acquisition of the data associated with the biological sample is performed at a first location and the imputing of the data into the model is performed at a second location different than the first location. Unless the data maps identically to the model, the data would have an inherent effect on the position of the particular clusters within the discriminatory pattern, if it is allowed to affect the model. The modeling software can keep track of the net effect on the model that each sample received has on the position of the model. If the model has drifted outside of a predetermined tolerance, the model can be updated.

7333896, Feb 19, 2008

Jul 28, 2003

10/628137

Ben A. Hitt - Gaithersburg MD, US
Peter J. Levine - Potomac MD, US

Correlogic Systems, Inc. - Rockville MD
The United States of America as represented by the Department of Health and Human Services - Washington DC

G06F 19/00, G01N 24/00

702 19, 436173

The present invention relates to a method of quality assurance/quality control for high-throughput bioassay processes. The method includes generating a bioassay process model, and then comparing spectral data based on a combination of a biochip and a test serum to the bioassay process model to determine if the test sample and the bioassay process are producing acceptable data. Alternatively, the method may include comparing spectral data based on a combination of serum and diluents used in an electrospray process to the bioassay process model. If the bioassay process and test sample fall within the model, then the spectrum produced may be further analyzed.

2008010, May 1, 2008

Jan 2, 2008

11/968262

Ben Hitt - Gaithersburg MD, US
Peter Levine - Potomac MD, US
Emanuel Petricoin - Dunkirk MD, US

C40B 50/02

506024000

The present invention relates to a method of quality assurance/quality control for high-throughput bioassay processes. The method includes generating a bioassay process model, and then comparing spectral data based on a combination of a biochip and a test serum to the bioassay process model to determine if the test sample and the bioassay process are producing acceptable data. Alternatively, the method may include comparing spectral data based on a combination of serum and diluents used in an electrospray process to the bioassay process model. If the bioassay process and test sample fall within the model, then the spectrum produced may be further analyzed.

2008019, Aug 14, 2008

Jan 2, 2008

11/968260

Ben A. Hitt - Gaithersburg MD, US
Peter J. Levine - Potomac MD, US
Timothy A. Coleman - Derwood MD, US

G01N 33/48

702 19

The invention relates to a method of quality assurance/quality control for high-throughput bioassay processes. The method permits monitoring of an entire system for obtaining spectral data from biological samples. Generally, the method includes generating a bioassay process model, comparing a test sample against the bioassay process model. The bioassay process model may be based on the position of a centroid in n-dimensional space. The comparing may include comparing the location of a centroid associated with the test model against the centroid associated with the control model to determine the distance between the two centroids. By generating a trend plot of the distance between the centroid associated with the test sample and the centroid associated with the control model, overall system performance may be monitored over time.

7395160, Jul 1, 2008

Jul 28, 2003

10/628136

Ben A. Hitt - Severn MD, US
Peter J. Levine - Potomac MD, US
Timothy A. Coleman - Derwood MD, US

Correlogic Systems, Inc. - Bethesda MD

G06F 19/00, G01N 24/00

702 19, 436173

The present invention relates to a method of quality assurance/quality control for high-throughput bioassay processes. The method includes generating a bioassay process model, and then comparing spectral data based on a combination of a biochip and a test serum to the bioassay process model to determine if the test sample and the bioassay process are producing acceptable data. Alternatively, the method may include comparing spectral data based on a combination of serum and diluents used in an electrospray process to the bioassay process model. If the bioassay process and test sample fall within the model, then the spectrum produced may be further analyzed.

6925389, Aug 2, 2005

Jul 18, 2001

09/906661

Ben A. Hitt - Severn MD, US
Peter J. Levine - Potomac MD, US
Lance A. Liotta - Bethesda MD, US

Correlogic Systems, Inc., - Bethesda MD
The United States of America as Represented by the Department of Health and Human Services - Washington DC

G01N033/48, G01N033/50, G06F007/00, G06G007/48

702 19, 702 20, 702 22, 702 27, 702 30, 702 32, 707 3, 707102, 435 6, 435 71

The invention describes a process for determining a biological state through the discovery and analysis of hidden or non-obvious, discriminatory biological data patterns. The biological data can be from health data, clinical data, or from a biological sample, (e. g. , a biological sample from a human, e. g. , serum, blood, saliva, plasma, nipple aspirants, synovial fluids, cerebrospinal fluids, sweat, urine, fecal matter, tears, bronchial lavage, swabbings, needle aspirantas, semen, vaginal fluids, pre-ejaculate. ), etc. which is analyzed to determine the biological state of the donor. The biological state can be a pathologic diagnosis, toxicity state, efficacy of a drug, prognosis of a disease, etc. Specifically, the invention concerns processes that discover hidden discriminatory biological data patterns (e. g. , patterns of protein expression in a serum sample that classify the biological state of an organ) that describe biological states.

2005026, Nov 24, 2005

Jul 27, 2005

11/189808

Ben Hitt - Severn MD, US
Peter Levine - Potomac MD, US
Emanuel Petricoin - Dunkirk MD, US
Lance Liotta - Bethesda MD, US

C12Q001/68, G06F019/00, G01N033/48, G01N033/50

435006000, 702019000

The invention describes a process for determining a biological state through the discovery and analysis of hidden or non-obvious, discriminatory biological data patterns. The biological data can be from health data, clinical data, or from a biological sample, (e.g., a biological sample from a human, e.g., serum, blood, saliva, plasma, nipple aspirants, synovial fluids, cerebrospinal fluids, sweat, urine, fecal matter, tears, bronchial lavage, swabbings, needle aspirantas, semen, vaginal fluids, pre-ejaculate.), etc. which is analyzed to determine the biological state of the donor. The biological state can be a pathologic diagnosis, toxicity state, efficacy of a drug, prognosis of a disease, etc. Specifically, the invention concerns processes that discover hidden discriminatory biological data patterns (e.g., patterns of protein expression in a serum sample that classify the biological state of an organ) that describe biological states.

2006006, Mar 23, 2006

Mar 30, 2005

11/093018

Ben Hitt - Wheeling WV, US
Peter Levine - Potomac MD, US

G06F 19/00

702022000

A well-controlled serum study set (n=248) from women being followed and evaluated for the presence of ovarian cancer was used to extend serum proteomic pattern analysis to a higher resolution mass spectrometer instrument platform to explore the existence of multiple distinct highly accurate diagnostic sets of features present in the same mass spectrum. Multiple highly accurate diagnostic proteomic feature sets exist within human sera mass spectra. Using high-resolution mass spectral data, at least 56 different patterns were discovered that achieve greater than 85% sensitivity and specificity in testing and validation. Four of those feature sets exhibited 100% sensitivity and specificity in blinded validation. The sensitivity and specificity of diagnostic models generated from high-resolution mass spectral data were superior (P